Article

Microplasmin receives orphan drug protection

Dublin-The FDA has classified a new microplasmin compound for use in pediatric vitrectomy as an orphan drug.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
Image credit: Ophthalmology Times; Dean McGee Eye Institute resident Ashley Ooms, MD, explores gray area strabismus surgery complications in AUPO poster
J. Peter Campbell, MD, MPH
Related Content
Japanese researchers link outdoor time to rapid increase in choroidal thickness
July 31st 2025

Japanese researchers link outdoor time to rapid increase in choroidal thickness

ROP: Treating and preventing blindness in preterm babies
July 31st 2025

ROP: Treating and preventing blindness in preterm babies

Children with ADHD may be less likely to develop myopia, study suggests
July 31st 2025

Children with ADHD may be less likely to develop myopia, study suggests

Managing a changing landscape of IRD pediatric cases
July 31st 2025

Managing a changing landscape of IRD pediatric cases

Study shows ceftriaxone found effective in treating congenital syphilis
July 31st 2025

Study shows ceftriaxone found effective in treating congenital syphilis

European Commission approves low-dose atropine eye drop Ryjunea from Santen
July 31st 2025

European Commission approves low-dose atropine eye drop Ryjunea from Santen

© 2025 MJH Life Sciences

All rights reserved.